CalciMedica, a clinical-stage biotechnology company developing CRAC inhibitors for the treatment of inflammatory diseases, announced it has raised $21 Million in Series D Financing to support the clinical development of a portfolio of CRAC channel inhibitors including AuxoraTM which is being evaluated in an ongoing clinical trial in severe and critical COVID-19 pneumonia, and in a Phase 2b trial in acute pancreatitis.
Auxora is currently under evaluation in a blinded, placebo-controlled clinical trial enrolling up to 400 patients with severe and critical COVID-19 pneumonia. To date over 200 patients have been randomized. Patients are receiving either Auxora or matched placebo in addition to standard of care, which includes dexamethasone and may include remdesivir.
